After the approval of Fosamax in 1995 by the FDA, Merck & Co launched a marketing campaign to promote the preventive aspects of this drug for osteoporosis and osteopenia. Part of that campaign saw a more than 10-fold increase in bone measuring devices, sponsored by the same drug manufacturers, to target healthy, middle-aged women, despite a lack of evidence that these machines or drugs actually benefited these women... Full Text